Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 31, 2015, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $261.44 to $13,995,847.04.

Highlighted Stocks Traded by Insiders:

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 180,000 shares at $73.94 on March 31, 2015. Following this transaction, the 10% Owner owned 131.0 million shares meaning that the stake was reduced by 0.14% with the 180,000-share transaction.

The shares most recently traded at $71.78, down $2.16, or 3.01% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 194,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 324,548
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 1.5 million

The average volume for Eli Lilly and has been 4.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $82.1 billion and is part of the health care sector and drugs industry. Shares are up 5.31% year-to-date as of the close of trading on Tuesday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The stock currently has a dividend yield of 2.71%. The company has a P/E ratio of 33.1. Currently, there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings

rates Eli Lilly and as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biota Pharmaceuticals (BOTA) - FREE Research Report

Patti Joseph M, who is Ceo at Biota Pharmaceuticals, bought 20,000 shares at $2.28 on March 31, 2015. Following this transaction, the Ceo owned 121,128 shares meaning that the stake was boosted by 19.78% with the 20,000-share transaction.

The shares most recently traded at $2.29, up $0.01, or 0.24% since the insider transaction. Historical insider transactions for Biota Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 10,000

The average volume for Biota Pharmaceuticals has been 162,100 shares per day over the past 30 days. Biota Pharmaceuticals has a market cap of $79.3 million and is part of the health care sector and drugs industry. Shares are up 2.68% year-to-date as of the close of trading on Tuesday.

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Currently, there are no analysts who rate Biota Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BOTA - FREE

TheStreet Quant Ratings

rates Biota Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Biota Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

New York & Company (NWY) - FREE Research Report

Toal Sheamus, who is EVP and CFO at New York & Company, bought 12,000 shares at $2.34 on March 31, 2015. Following this transaction, the EVP and CFO owned 225,339 shares meaning that the stake was boosted by 5.62% with the 12,000-share transaction.

The shares most recently traded at $2.48, up $0.14, or 5.56% since the insider transaction. Historical insider transactions for New York & Company go as follows:

  • 4-Week # shares sold: 47,272
  • 12-Week # shares sold: 47,272
  • 24-Week # shares sold: 47,272

The average volume for New York & Company has been 83,900 shares per day over the past 30 days. New York & Company has a market cap of $157.4 million and is part of the services sector and retail industry. Shares are down 5.3% year-to-date as of the close of trading on Tuesday.

New York & Company, Inc., together with its subsidiaries, operates as a specialty retailer of women's fashion apparel and accessories in the United States. Currently, there is 1 analyst who rates New York & Company a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NWY - FREE

TheStreet Quant Ratings

rates New York & Company as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

New York & Company Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null